EASL Conference. 28th Meeting of the European Association for the Study of The Liver was scheduled to be held in Istanbul, Turkey March 28-April 1, 2003. Canceled due to war. The Danish Hepatitis Association is reporting selected key abstracts.
          

Hepatitis B

  • Pegasys (pegintergferon alfa-2a) Improves Response Rates in HBeAg-positive Chronic Hepatitis B Patients with Genotypes B or C

    •   
  • Study of Epivir-HBV (lamivudine) Compared to Epivir-HBV Plus Hepsera (adevofir dipivoxil) for Treatment of Naïve Patients with Chronic Hepatitis B: One-Year Analysis

    •   
  • Two Year Results Show Significant and Persistent Reductions in HBV DNA and ALT from Hepsera (adefovir dipivoxil) Treatment for Presumed Precore Mutant Chronic Hepatitis B

    •   
  • Viread (tenofovir) Effectively Suppresses HBV in Different Patient Groups with Epivir-HBV (lamivudine)-Resistant HBV

    •   
  • Two Year Results Show Significant and Persistent Reductions in HBV DNA and ALT from Hepsera (adefovir dipivoxil) Treatment for Presumed Precore Mutant Chronic Hepatitis B

    •   

    Hepatitis C

  • After 24 Weeks of Pegasys/Ribavirin Combination Treatment, Pegasys Monotherapy for 22 Weeks Results in Higher Rate of Virological Breakthrough Than Continued Combination Therapy

    •   
  • Therapy with Pegasys + Ribavirin + Amantadine Shows Significantly Better 6-month Virological Response Than Treatment with Roferon + Ribavirin + Amantadine in Non Responders Previously Treated with Roferon + Ribavirin

    •   
  • Interim Analysis of Bi-Tri-Peg Study: Triple Therapy with PEG-Intron Plus Ribavirin Plus Amantadine vs Standard Therapy in Non-responders

    •   
  • Pharmacokinetics of Pegasys Compared to PEG-Intron in Treatment-Naïve Patients with Chronic Hepatitis C

    •   
  • Retreatment of Non Responders with Pegasys Plus Ribavirin and Amantadine Produces a Clinically Significant Response Rate

    •   
  • Pegasys Plus Ribavirin Is Safe and Effective Treatment for Patients with Chronic Hepatitis C and Compensated Cirrhosis

    •   
  • Pegasys (peginterferon alfa-2a) Alone or in Combination with Copegus (ribavirin) Produces a Long-lasting Sustained Virological Response

    •   
    		 

    << Previous